Table 2 Clinical data.

All patients recruited in this study have a diagnosis of RRMS defined according to Poser’s diagnostic criteria. None of the RRMS patients received corticosteroids in the 3 months before the EGDs (time of intestinal biopsy collection). RRMS patients were divided into two subgroups on the basis of evidence of disease activity at 2-year follow-up: RRMS patients with no evidence of disease activity in the 2-year follow-up were classified as NEDA (n = 9), whereas RRMS patients with evidence of disease activity were classified as EDA (n = 10). All RRMS patients recruited in this study were undergoing different therapeutic immunomodulatory regimens (IFN-β, GA, and fingolimod) at the time of EGD and intestinal tissue sample analysis.

MS patient IDSexAge (years)Disease activity (2-year follow-up)EDSSCurrent therapy
MS001F38NEDA3Fingolimod
MS002M49EDA3IFN-β
MS003F27EDA2IFN-β
MS004F49NEDA5.5GA
MS005F38EDA1.5IFN-β
MS006M42NEDA2GA
MS007M43EDA1.5GA
MS008M37EDA2Fingolimod
MS009M35EDA4GA
MS010M57EDA4GA
MS011F55NEDA1.5GA
MS012F26NEDA5GA
MS013F29NEDA1IFN-β
MS016M27NEDA1.5IFN-β
MS017F42NEDA1.5IFN-β
MS018F57EDA3.5Fingolimod
MS020F25EDA1GA
MS021F56NEDA2IFN-β
MS022M40EDA1GA